Overview: Malaysia’s Biggest Listing in Nine Years
Sunway Healthcare Holdings Bhd (SHH) has officially launched its initial public offering (IPO), aiming to raise RM2.86 billion ($734 million) on Bursa Malaysia’s Main Market. This marks the country’s largest listing in nine years — since Lotte Chemical Titan Holding Bhd raised RM3.77 billion in July 2017.
The healthcare arm of conglomerate Sunway Bhd unveiled its prospectus on Friday, February 27, 2026, and immediately began accepting investor orders. Furthermore, this IPO signals a major milestone for Malaysia’s private healthcare sector, drawing interest from both domestic and international institutional investors.
IPO Price, Structure, and Timeline
Key Offer Details
SHH priced its IPO at RM1.45 per share, offering up to 1.97 billion shares in total. The offer comprises two components:
- Offer for sale: Up to 1.39 billion existing shares (12.1% of enlarged share capital)
- Public issue: 575 million new shares (5% of enlarged share capital)
Retail investor applications close on March 5, 2026, while the institutional offering ends on March 6, 2026. Consequently, the company targets its official listing date on March 18, 2026.
The IPO involves both a retail tranche of 345 million shares and an institutional tranche of up to 1.62 billion shares. Six investment banks — Maybank Investment Bank, AmInvestment Bank, Affin Hwang Investment Bank, CIMB Investment Bank, RHB Investment Bank, and Kenanga Investment Bank — have signed underwriting agreements to support the deal.
Valuation and Market Comparison
How Does SHH Stack Up Against Peers?
At RM1.45 per share, SHH carries a market capitalisation of RM16.7 billion. This translates to a price-earnings (PE) multiple of 64.8 times and an enterprise value-to-EBITDA (EV/EBITDA) multiple of 36.1 times, based on its net profit of RM257.5 million for the financial year ending December 31, 2024.
These valuations are notably higher than its listed peers. For comparison, IHH Healthcare Bhd trades at a trailing PE ratio of 30 times with EV/EBITDA of 17.7 times. Meanwhile, KPJ Healthcare Bhd trades at a PE ratio of 37.4 times with EV/EBITDA of 15.4 times.
Analysts point to SHH’s size, growth pipeline, and market leadership as factors that support the premium valuation. However, some market observers note that current sentiment, influenced by global equity market volatility, may test investor appetite at these price levels.
How IPO Proceeds Will Be Used
Capital Allocation Breakdown
SHH plans to raise approximately RM834 million from new share issuance. Additionally, Sunway Group and Greenwood Capital will raise up to RM730 million and RM129 million respectively through the offer for sale.
The allocation of proceeds from the public issue breaks down as follows:
- 66.5% for capital expenditure to expand existing hospitals
- 29.9% for redemption of sukuk wakalah
- 3.6% for listing fees and related expenses
Sunway Group will use its portion of the offer-for-sale proceeds to reduce borrowings, support working capital, and cover listing expenses. Thus, the IPO serves both growth and balance sheet optimization goals.
Hospital Network and Expansion Plans
Building Malaysia’s Largest Private Hospital Network
SHH currently operates one of Malaysia’s largest private hospital networks, with a total licensed bed count of 1,805 and a bed capacity of 1,982. Its flagship facility is the 848-bed Sunway Medical Centre in Sunway City, Kuala Lumpur. The group also runs hospitals in Cheras, Penang, Damansara, and Ipoh, along with ancillary services covering fertility clinics, home care, and senior living.
Looking ahead, SHH plans to open new hospitals in Seremban, Iskandar Puteri, and Putrajaya, along with a fertility centre in Kota Bharu. A new 401-bed hospital in Iskandar Puteri alone will cost RM766 million, and upgrades to existing facilities will add nearly RM850 million more in investment.
Together, these expansions aim to more than double SHH’s total bed capacity to over 3,400 beds by 2032. This growth roadmap gives the company a compelling long-term story that underpins its premium IPO valuation.
Cornerstone Investors and Underwriters
Strong Institutional Backing
The IPO has attracted strong institutional support, with 20 cornerstone investors confirmed. These include major names such as the Employees Provident Fund (EPF), Lembaga Tabung Haji, and JPMorgan Asset Management (Singapore). Their participation reflects confidence in SHH’s long-term fundamentals.
Post-IPO, Sunway, through SunCity, will retain a 69.5% equity stake in SHH. Greenwood Capital, a Singapore-based firm previously holding a 16% pre-IPO stake, will retain 7.5% after the listing.
Market Outlook and Growth Story
Why Investors Are Watching This IPO Closely
Sunway Healthcare’s IPO arrives at a crucial time for Malaysia’s healthcare sector. The Bursa Malaysia Healthcare Index fell more than 34% over the past year, making it the worst-performing index in 2025. Nevertheless, SHH’s promoters believe the company’s scale, strong brand, and clear expansion roadmap can attract long-term investors.
“SHH has a growth story, especially with new hospitals coming online, which could justify the valuations,” one market observer noted. Moreover, Securities Commission Malaysia granted listing approval in December 2025, adding regulatory confidence to the offering.
In conclusion, this landmark IPO signals a new chapter for private healthcare investment in Malaysia. If successful, it will be the country’s biggest capital market deal in nearly a decade — and a strong indicator of growing investor confidence in the region’s healthcare industry.
